Clinical guidelines now recommend chemoimmunotherapy combinations as the standard first-line treatment for NSCLC, irrespective of the expression of tumor-programmed cell death ligand 1 (PD-L1), which is a predictive biomarker in NSCLC [2,3]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.